Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2015 Sep 9

PMID 26348965

Citations 1854

Authors

Elvin Blanco

Haifa Shen

Mauro Ferrari

Affiliations

Soon will be listed here.

Abstract

Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.

Citing Articles

Advances in targeted therapy for tumor with nanocarriers: A review.

Cheng H, Liao J, Ma Y, Sarwar M, Yang H Mater Today Bio. 2025; 31:101583.

PMID: 40061211 PMC: 11889621. DOI: 10.1016/j.mtbio.2025.101583.

ROS-responsive simvastatin nano-prodrug based on tertiary amine-oxide zwitterionic polymer for atherosclerotic therapy.

Yang H, Guo M, Guan Q, Zhang L, Liu M, Li H J Nanobiotechnology. 2025; 23(1):176.

PMID: 40050920 PMC: 11884140. DOI: 10.1186/s12951-025-03232-1.

Biomimetic-Nanoparticle-Enhanced Photothermal Immunotherapy: Targeted Delivery of Near-Infrared Region II Agents and Immunoadjuvants for Tumor Immunogenicity.

Yu Y, Li W, Yu Q, Ye J, Wang H, Li Y Biomater Res. 2025; 29:0151.

PMID: 40040955 PMC: 11876542. DOI: 10.34133/bmr.0151.

Exploring the application of metal-based photothermal agents in photothermal therapy combined with immune checkpoint therapy.

Xie B, Xiao Z, Ling J, Peng Y, Chen T Front Pharmacol. 2025; 16:1553158.

PMID: 40017598 PMC: 11865196. DOI: 10.3389/fphar.2025.1553158.

Promotion of NLRP3 autophagosome degradation by PV-K nanodevice for protection against macrophage pyroptosis-mediated lung injury.

Fan Y, Mei J, Shen Y, Gao Y, Zhao L, Meng S J Nanobiotechnology. 2025; 23(1):148.

PMID: 40016743 PMC: 11866711. DOI: 10.1186/s12951-025-03219-y.

References

Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T . Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol. 2008; 2(4):249-55. PMC: 2740330. DOI: 10.1038/nnano.2007.70. View

Docter D, Distler U, Storck W, Kuharev J, Wunsch D, Hahlbrock A . Quantitative profiling of the protein coronas that form around nanoparticles. Nat Protoc. 2014; 9(9):2030-44. DOI: 10.1038/nprot.2014.139. View

Chiappini C, Tasciotti E, Fakhoury J, Fine D, Pullan L, Wang Y . Tailored porous silicon microparticles: fabrication and properties. Chemphyschem. 2010; 11(5):1029-35. PMC: 2920042. DOI: 10.1002/cphc.200900914. View

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

Salvati A, Pitek A, Monopoli M, Prapainop K, Bombelli F, Hristov D . Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013; 8(2):137-43. DOI: 10.1038/nnano.2012.237. View

Parodi A, Quattrocchi N, van de Ven A, Chiappini C, Evangelopoulos M, Martinez J . Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol. 2012; 8(1):61-8. PMC: 3751189. DOI: 10.1038/nnano.2012.212. View

OBrien M, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A . Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004; 15(3):440-9. DOI: 10.1093/annonc/mdh097. View

Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C . Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 2002; 10(4):317-25. DOI: 10.1080/10611860290031877. View

Longmire M, Choyke P, Kobayashi H . Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond). 2008; 3(5):703-17. PMC: 3407669. DOI: 10.2217/17435889.3.5.703. View

10.

Wong H, Bendayan R, Rauth A, Wu X . Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release. 2006; 116(3):275-84. DOI: 10.1016/j.jconrel.2006.09.007. View

11.

Decuzzi P, Lee S, Bhushan B, Ferrari M . A theoretical model for the margination of particles within blood vessels. Ann Biomed Eng. 2005; 33(2):179-90. DOI: 10.1007/s10439-005-8976-5. View

12.

Braet F, Wisse E, Bomans P, Frederik P, Geerts W, Koster A . Contribution of high-resolution correlative imaging techniques in the study of the liver sieve in three-dimensions. Microsc Res Tech. 2007; 70(3):230-42. DOI: 10.1002/jemt.20408. View

13.

Hawkins M, Soon-Shiong P, Desai N . Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008; 60(8):876-85. DOI: 10.1016/j.addr.2007.08.044. View

14.

Arvizo R, Miranda O, Moyano D, Walden C, Giri K, Bhattacharya R . Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One. 2011; 6(9):e24374. PMC: 3172229. DOI: 10.1371/journal.pone.0024374. View

15.

Attia A, Yang C, Tan J, Gao S, Williams D, Hedrick J . The effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micelles. Biomaterials. 2013; 34(12):3132-40. DOI: 10.1016/j.biomaterials.2013.01.042. View

16.

Ibrahim N, Samuels B, Page R, Doval D, Patel K, Rao S . Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005; 23(25):6019-26. DOI: 10.1200/JCO.2005.11.013. View

17.

Monsky W, Fukumura D, Gohongi T, Ancukiewcz M, Weich H, Torchilin V . Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 1999; 59(16):4129-35. View

18.

Matsumura Y, Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12 Pt 1):6387-92. View

19.

Gratton S, Ropp P, Pohlhaus P, Luft J, Madden V, Napier M . The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008; 105(33):11613-8. PMC: 2575324. DOI: 10.1073/pnas.0801763105. View

20.

Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X . Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci. 2007; 10(3):350-7. View